ADHD

  • Press Release
  • No Likes

ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI 150 150 Press Release

FREMONT, CA – July 9, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II clinical trials of their medication…

read more
  • Press Release
  • No Likes

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study 150 150 Press Release

FREMONT, CA, Dec. 07, 2023 (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company’s eight-week long ADHD Phase II part II clinical…

read more
  • Press Release
  • No Likes

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production 150 150 Press Release
BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. This agreement marks the second year of a partnership that grants Define Biotech the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan. read more
  • Russ Jaimes
  • No Likes

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF 150 150 Russ Jaimes
ABVC based in Fremont, California, signed a collaborative agreement with MerDury BioPharma on June 1st, 2023 to co-develop new drug products leveraging MerDury’s StackDoseTM platform technology. read more
  • Press Release
  • No Likes

Summer 2023: Investor Presentation
Summer 2023: Investor Presentation 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC) has announced the launch of its new pitch deck, presenting transformative advancements in biopharmaceuticals to potential investors. read more
  • Press Release
  • No Likes

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization
ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization 150 150 Press Release
ABVC based in Fremont, California, signed a collaborative agreement with MerDury BioPharma on June 1st, 2023 to co-develop new drug products leveraging MerDury’s StackDoseTM platform technology. read more
  • Press Release
  • No Likes

ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the site initiation visits (SIV) at the University of California San Francisco (UCSF) Medical Center was conducted on March 29, 2023. read more
  • Press Release
  • No Likes

ABVC BioPharma Provides 2023 Pipeline Update
ABVC BioPharma Provides 2023 Pipeline Update 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023 read more
  • Press Release
  • No Likes

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, read more

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.